The FCF Biotech Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US-Biotech sector.
As of the end of June 2021, we identify the following current VC trends in the US-Biotech sector:
- In 2021, overall Biotech funding in the USA has reached USD 19,474m so far
- Top 5 deals exceed USD 330m each, largest transaction amounted to USD 735m in Treeline Biosciences, Inc.
- Logos Capital (USA) leads the Top 5 Investors (by deal volume), followed by ARCH Venture Partners (USA) and RA Capital Management (USA)
- Oncology dominates as the top indication
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
FCF Life Sciences Venture Capital Monitor – Europe 08/2021 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 08/2021”. The Monitor is a monthly published overview of venture capital trends in the European Life
New record high in VC funding from U.S. investors raised by European life sciences companies
The venture capital funding volume raised by European life sciences companies from U.S. investors has experienced an extraordinary growth so far. As of end of August 2021, the gross volume amounts to EUR 3.1bn, which
Venture capital financing of European life sciences companies could exceed the EUR 10 billion mark in 2021 for the first time
Venture capital financing of European life sciences companies could exceed the EUR 10 billion mark in 2021 for the first time FCF Life Sciences Venture Capital Monitor: Venture capital deal volume in Europe increases to
Acquisition of German diagnostics company EUROIMMUN by PerkinElmer in the top 10 diagnostics M&A deals ranking
The top 10 diagnostics M&A deals of the last five years (by deal size) range from EUR 0.8bn to EUR 20.3bn, with an average deal size of EUR 4.1bn. The largest deal by far was
FCF Biotech Venture Capital Monitor – USA 07/2021 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 07/2021”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
